Advertisement

Pharmaceutical Research

, Volume 27, Issue 9, pp 1977–1986 | Cite as

Inhalable Microparticles as Carriers for Pulmonary Delivery of Thymopentin-Loaded Solid Lipid Nanoparticles

Research Paper

ABSTRACT

Purpose

Microparticles containing solid lipid nanoparticles (SLNs) are receiving increased attention as carriers for the lung delivery of the SLNs. Thus, we aim to prepare the hybrid microparticles and thoroughly evaluate their feasibility for the pulmonary drug delivery.

Methods

The microparticles were prepared by co-spray-drying the thymopentin (TP5)-loaded SLNs with bulking agents. Thereafter, we systematically estimated the potential of the microparticles as the carriers for the pulmonary delivery of the SLNs, including the investigations of their characteristics, aerodynamic properties, pharmacokinetics and pharmacodynamics.

Results

The spherical and hollow microparticles presented a size of 4.1 ± 0.1 μm and a low tap density of 0.175 ± 0.02 g/cm3. In addition, the microparticles showed a high aerosolization efficiency (emitted dose of 98.0% ± 1.23% and respirable fraction of 51.07% ± 1.21%). Furthermore, the SLNs could be easily recovered from the microparticles without essential changes on their characteristics and the drug release behavior. The pharmacokinetic and pharmacodynamic studies suggested that, compared to i.v. TP5 solution, the bioavailability and therapeutic efficacy of TP5 were remarkably strengthened after the pulmonary administration of the microparticles.

Conclusions

Taken together, we believe the microparticles were suitable for inhalation and possesed an ample potential for the pulmonary delivery of the SLNs.

KEY WORDS

pulmonary delivery microparticles solid lipid nanoparticles spray-drying thymopentin 

ABBREVIATIONS

AUC

area under the curve

CLSM

confocal laser scanning microscope

ED

emitted dose

EE%

encapsulation efficacy

DPI

dry powder inhaler

FITC

fluorescein isothiocyanate

HPLC

high performance liquid chromatography

i.v.

intravenous injection

mAb

monoclonal Antibodies

MRT

mean residence time

PBS

phosphate buffer

PDI

polydispersity index

RD

respirable dose

RF

respirable fraction

SD

standard deviation

SEM

scanning electron microscopy

SLNs

solid lipid nanoparticles

SOD

superoxide dismutase

TP5

thymopentin

TSI

twin stage impinger

W/O

water in oil

W/O/W

water in oil in water

Notes

ACKNOWLEDGMENTS

This work was funded by the National S & T Major Project of China (Grant No: 2009ZX09310–002) and the National Science Foundation of PR China (No.30873165).

REFERENCES

  1. 1.
    Goldstein G, Scheid M, Boyse E, Schlesinger D, Wauwe JV. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science. 1979;204:1309–10.CrossRefPubMedGoogle Scholar
  2. 2.
    Clumeck N, Cran S, Van de Perre P, Lemone FM, Duchateau J, Bolla K. Thymopentin treatment in AIDS and pre-AIDS patients. Immunol Res. 1985;4:58–62.Google Scholar
  3. 3.
    Singh VK, Biswas S, Mathur KB, Haq W, Garg SK, Agarwal SS. Thymopentin and splenopentin as immunomodulators. Immunol Res. 1998;17:345–68.CrossRefPubMedGoogle Scholar
  4. 4.
    Tischio JP, Patrick JE, Weintraub HS, Chasin M, Goldstein G. Short in vitro half-life of thymopoietin32–36 pentapeptide in human plasma. Int J Pept Protein Res. 1979;14:479–84.PubMedGoogle Scholar
  5. 5.
    Jalalipour M, Gilani K, Tajerzadeh H, Najafabadi AR, Barghi M. Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents. Int J Pharm. 2008;352:209–16.PubMedGoogle Scholar
  6. 6.
    Ungaro F, Rosa GD, Miro A, Quaglia F, Rotonda MIL. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci. 2006;28:423–32.CrossRefPubMedGoogle Scholar
  7. 7.
    Salama RO, Traini D, Chan H-K, Sung A, Ammit AJ, Young PM. Preparation and evaluation of controlled release microparticles for respiratory protein therapy. J Pharm Sci. 2009;98:2709–17.CrossRefPubMedGoogle Scholar
  8. 8.
  9. 9.
    Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, Yeo Y. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials. 2009;30:1947–53.CrossRefPubMedGoogle Scholar
  10. 10.
    Seville PC, Learoyd TP, Li H-Y, Williamson IJ, Birchall JC. Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol. 2007;178:40–50.CrossRefGoogle Scholar
  11. 11.
    Sivadasa N, O’Rourkea D, Tobina A, Buckley V, Ramtoolaa Z, Kellya JG, et al. A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int J Pharm. 2008;358:159–67.CrossRefGoogle Scholar
  12. 12.
    Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci. 2002;99:12001–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Hadinoto K, Phanapavudhikul P, Kewu Z, Tan RBH. Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs. Ind Eng Chem Res. 2006;45:3697–706.CrossRefGoogle Scholar
  14. 14.
    Hadinoto K, Zhu K, Tan RBH. Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery. Int J Pharm. 2007;341:195–206.CrossRefPubMedGoogle Scholar
  15. 15.
    Shama JO-H, Zhang Y, Finlay WH, Roaa WH, Löbenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm. 2004;269:457–67.CrossRefGoogle Scholar
  16. 16.
    Makino K, Yamamoto N, Higuchi K, Harada N, Ohshima H, Terada H. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres. Colloids Surf B Biointerfaces. 2003;27:33–9.CrossRefGoogle Scholar
  17. 17.
    García-Fuentes M, Torres D, Alonso MJ. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf B Biointerfaces. 2002;27:159–68.CrossRefGoogle Scholar
  18. 18.
    Kho K, Hadinoto K. Aqueous re-dispersibility characterization of spray-dried hollow spherical silica nano-aggregates. Powder Technol. 2010;198:354–63.CrossRefGoogle Scholar
  19. 19.
    Freitas C, Müller RH. Spray-drying of solid lipid nanoparticles (SLN™). Eur J Pharm Biopharm. 1998;46:145–51.CrossRefPubMedGoogle Scholar
  20. 20.
    Grenha A, Seijo B, Serra C, Remuñán-López C. Chitosan nanoparticle-loaded mannitol microspheres: structure and surface characterization. Biomacromolecules. 2007;8:2072–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Grenha A, Remuñán-López C, Carvalho ELS, Seijo B. Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Pharm Biopharm. 2008;69:83–93.CrossRefPubMedGoogle Scholar
  22. 22.
    Gómez-Gaete C, Fattal E, Silva L, Besnard M, Tsapis N. Dexamethasone acetate encapsulation into Trojan particles. J Control Release. 2008;128:41–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Liu J, Gong T, Wang CG, Zhong ZR, Zhang ZR. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm. 2007;340:153–62.CrossRefPubMedGoogle Scholar
  24. 24.
    Bosquillon C, Préat V, Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J Control Release. 2004;96:233–44.CrossRefPubMedGoogle Scholar
  25. 25.
    Wang J, Lu WL, Liang GW, Wu KC, Zhang C-G, Zhang X, et al. Pharmacokinetics, toxicity of nasal cilia and immunomodulating effects in sprague-dawley rats following intranasal delivery of thymopentin with or without enhancers. Peptides. 2006;27:826–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Treitinger A, Spada C, Verdi JC, Miranda AFB, Oliveira OV, Silveira MVS, et al. Decreased antioxidant defence in individuals infected by the human immunodeficiency virus. Eur J Clin Investig. 2001;30:454–9.CrossRefGoogle Scholar
  27. 27.
    Yin YS, Chen DW, Qiao MX, Lu Z, Hu HY. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J Control Release. 2006;116:337–45.CrossRefPubMedGoogle Scholar
  28. 28.
    French DL, Edwards DA, Niven RW. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci. 1996;27:769–83.CrossRefGoogle Scholar
  29. 29.
    Maury M, Murphy K, Kumar S, Mauerer A, Lee G. Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G. Eur J Pharm Biopharm. 2005;59:251–61.CrossRefPubMedGoogle Scholar
  30. 30.
    Bosquillon C, Lombry C, Préat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release. 2001;70:329–39.CrossRefPubMedGoogle Scholar
  31. 31.
    Kibbe AH. Handbook of pharmaceutical excipients, London; 2000.Google Scholar
  32. 32.
    Souilliac PO, Middaugh CR, Rytting JH. Investigation of protein/carbohydrate interactions in the dried state. 2. Diffuse reflectance FTIR studies. Int J Pharm. 2002;235:207–18.CrossRefGoogle Scholar
  33. 33.
    Tzannis ST, Prestrelski SJ. Activity-stability consideration of trypsinogen during spray drying: effect of sucrose. J Pharm Sci. 1999;88:351–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Key Laboratory of Drug Targeting and Novel Drug Delivery Systems West China School of PharmacySichuan UniversityChengduPeople’s Republic of China

Personalised recommendations